BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fukushima, A.
Right arrow Articles by Ueno, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fukushima, A.
Right arrow Articles by Ueno, H.
Br J Ophthalmol 1999;83:973-979 ( August )

Suppression of induction of experimental immune mediated blepharoconjunctivitis by tolerogenic conjugates of the antigen and monomethoxypolyethylene glycol

Atsuki Fukushimaa, Koji Nishinoa, Hironori Yoshidaa, Masaru Takatab, Hisayuki Uenoa

a Department of Ophthalmology, Kochi Medical School, Nankoku City, Japan, b Department of Immunology, Kochi Medical School, Nankoku City, Japan

Correspondence to: Atsuki Fukushima, Laboratory of Immunology, Department of Ophthalmology, Kochi Medical School, Kohasu, Oko-cho, Nankoku 783-8505, Japan.

Accepted for publication 15 March 1999

AIM---Covalent conjugates consisting of diverse antigens coupled to optimal numbers of monomethoxypolyethylene glycol (mPEG) molecules have been shown to suppress antigen specific antibody formation. In this study, the possibility was examined that the same conjugates might prevent experimental immune mediated blepharoconjunctivitis (EC, formerly EAC) which had been shown to be caused by CD4+ T cells---that is, to cell mediated immunity.
METHODS---6-8 week old male Lewis rats were used. The test groups of rats received two intravenous injections, each of 300 µg, of a conjugate of ovalbumin mPEG (OVA(mPEG)11) in phosphate buffered saline (PBS), 14 and 28 days before the single immunisation with OVA in complete Freund's adjuvant. The rats were challenged 3 weeks later by eye drops containing OVA; 24 hours later they were sacrificed, and their eyes, blood, and lymph nodes were harvested for histological examination and determination of anti-OVA antibody titres and levels of cellular immunity. Two control groups received PBS or OVA in PBS before immunisation. Furthermore, the possibility that OVA(mPEG)11 may have induced OVA specific suppressor cells was tested by establishing the effects of the co-transfer of splenocytes from OVA(mPEG)11 treated rats with OVA primed lymph node cells on the manifestations of EC.
RESULTS---Either PBS or OVA pretreated rats, which had not received OVA(mPEG)11, developed high levels of antibodies and cell mediated immune responses to OVA, and application of eye drops led to blepharoconjunctivitis with massive cellular infiltration. In contrast, pretreatment with OVA(mPEG)11 prevented cellular infiltration into the lids and conjunctivas, as well as the formation of detectable humoral and cellular immunity against OVA. Co-transfer of splenocytes from OVA(mPEG)11 treated rats with OVA primed lymph node cells suppressed the cellular infiltration on application of OVA on the conjunctiva.
CONCLUSIONS---These data indicate that intravenous injection of OVA(mPEG)11 conjugates suppressed both humoral and cellular immunity by the effects of antigen specific suppressor cells, thus leading to the inhibition of development of EC.

© 1999 by British Journal of Ophthalmology




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1999 by the BMJ Publishing Group Ltd.